References

Unresolved reference

2025 · External reference

Unresolved reference

External reference

Vivax malaria: neglected and not benign

10.4269/ajtmh.2007.77.79 · 2007 · External reference

Estimating the proportion of Plasmodium vivax recurrences caused by relapse: a systematic review and meta-analysis

10.4269/ajtmh.20-0186 · 2020 · External reference

Plasmodium vivax latent liver stage infection and relapse: biological insights and new experimental tools

10.1146/annurev-micro-032421-061155 · 2021 · External reference

Plasmodium vivax: the potential obstacles it presents to malaria elimination and eradication

10.1186/s40794-022-00185-3 · 2022 · External reference

Global extent of chloroquine-resistant plasmodium vivax: a systematic review and meta-analysis

10.1016/s1473-3099(14)70855-2 · 2014 · External reference

Cost-effectiveness analysis of rapid diagnostic tests for G6PD deficiency in patients with Plasmodium vivax malaria in the Brazilian Amazon

10.1186/s12936-016-1140-x · 2016 · External reference

A library of Plasmodium vivax recombinant merozoite proteins reveals new vaccine candidates and protein-protein interactions

10.1371/journal.pntd.0004264 · 2015 · External reference

A comprehensive analysis of plasmodium circumsporozoite protein binding to hepatocytes

10.1371/journal.pone.0161607 · 2016 · External reference

Unlocking the potential of novel RTS, S/AS01, and R21/Matrix-M malaria vaccines in African nations

10.1002/hsr2.1797 · 2024 · External reference

Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice

10.1016/j.vaccine.2012.03.004 · 2012 · External reference

Immunogenicity of a prime-boost vaccine containing the circumsporozoite proteins of Plasmodium vivax in rodents

10.1128/iai.01410-13 · 2014 · External reference

Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models

10.1038/srep46482 · 2017 · External reference

Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria vaccine using Poly-ICLC (Hiltonol(R)) as adjuvant

10.1016/j.vaccine.2024.02.070 · 2024 · External reference

Vaccine containing the three allelic variants of the Plasmodium vivax circumsporozoite antigen induces protection in mice after challenge with a transgenic rodent malaria parasite

10.3389/fimmu.2017.01275 · 2017 · External reference

Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge

10.1038/s41598-017-19063-6 · 2018 · External reference

A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles

10.1038/s41598-021-96986-1 · 2021 · External reference

Phase 1/2a trial of Plasmodium vivax malaria vaccine candidate VMP001/AS01B in malaria-naive adults: safety, immunogenicity, and efficacy

10.1371/journal.pntd.0004423 · 2016 · External reference

Randomized clinical trial to assess the protective efficacy of a plasmodium vivax CS synthetic vaccine

10.1038/s41467-022-29226-3 · 2022 · External reference

What is known about the immune response induced by Plasmodium vivax malaria vaccine candidates?

10.3389/fimmu.2017.00126 · 2017 · External reference

Plasmodium vivax vaccine candidate MSP1 displays conserved B-cell epitope despite high genetic diversity

10.1016/j.meegid.2021.104929 · 2021 · External reference

Comparison of the immunogenic properties of recombinant proteins representing the Plasmodium vivax vaccine candidate MSP1(19) expressed in distinct bacterial vectors

10.1016/s0264-410x(01)00359-0 · 2001 · External reference

New malaria vaccine candidates based on the Plasmodium vivax merozoite surface protein-1 and the TLR-5 agonist Salmonella typhimurium FliC flagellin

10.1016/j.vaccine.2008.08.070 · 2008 · External reference

Immunogenicity of a recombinant protein containing the Plasmodium vivax vaccine candidate MSP1(19) and two human CD4+ T-cell epitopes administered to non-human primates (Callithrix jacchus jacchus)

10.1016/j.micinf.2006.03.012 · 2006 · External reference

Protective immunity in mice immunized with P. vivax MSP1(19)-based formulations and challenged with P. berghei expressing PvMSP1(19)

10.3389/fimmu.2020.00028 · 2020 · External reference

IUPred3: prediction of protein disorder enhanced with unambiguous experimental annotation and visualization of evolutionary conservation

10.1093/nar/gkab408 · 2021 · External reference

Statistical potential for assessment and prediction of protein structures

10.1110/ps.062416606 · 2006 · External reference

Unresolved reference

2010 · External reference

Protective malaria vaccine in mice based on the Plasmodium vivax circumsporozoite protein fused with the mumps nucleocapsid protein

10.3390/vaccines8020190 · 2020 · External reference

Poly I:C elicits broader and stronger humoral and cellular responses to a Plasmodium vivax circumsporozoite protein malaria vaccine than Alhydrogel in mice

10.3389/fimmu.2024.1331474 · 2024 · External reference

Safety, immunogenicity and efficacy of prime-boost vaccination with ChAd63 and MVA encoding ME-TRAP against Plasmodium falciparum infection in adults in Senegal

10.1371/journal.pone.0167951 · 2016 · External reference

Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model

10.1038/s41598-018-21369-y · 2018 · External reference

A chimeric protein-based malaria vaccine candidate induces robust T cell responses against Plasmodium vivax MSP1(19)

10.1038/srep34527 · 2016 · External reference

Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial

10.1016/s1473-3099(15)00239-x · 2015 · External reference

A multistage formulation based on full-length CSP and AMA-1 ectodomain of Plasmodium vivax induces high antibody titers and T-cells and partially protects mice challenged with a transgenic plasmodium berghei parasite

10.3390/microorganisms8060916 · 2020 · External reference

Recombinant Plasmodium vivax circumsporozoite surface protein allelic variants: antibody recognition by individuals from three communities in the Brazilian Amazon

10.1038/s41598-020-70893-3 · 2020 · External reference

Molecular epidemiology and genetic diversity of disappearing Plasmodium vivax in southern Thailand

10.1038/s41598-025-86578-8 · 2025 · External reference

Intrinsically disordered proteins in cellular signalling and regulation

10.1038/nrm3920 · 2015 · External reference

Structural ordering of the Plasmodium berghei circumsporozoite protein repeats by inhibitory antibody 3D11

10.7554/elife.59018 · 2020 · External reference

Structural basis of Plasmodium vivax inhibition by antibodies binding to the circumsporozoite protein repeats

10.7554/elife.72908 · 2022 · External reference

Malaria vaccines: recent advances and new horizons

10.1016/j.chom.2018.06.008 · 2018 · External reference

Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction

10.1073/pnas.1112648109 · 2012 · External reference

Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent plasmodium falciparum infection

10.1172/jci70349 · 2014 · External reference

Human antibodies fix complement to inhibit plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria

10.1016/j.immuni.2015.02.012 · 2015 · External reference

Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria

10.1186/1741-7015-12-108 · 2014 · External reference

Germinal center B cell and T follicular helper cell responses to viral vector and protein-in-adjuvant vaccines

10.4049/jimmunol.1502472 · 2016 · External reference